Abstract
The purpose of this study was to develop nanosuspension based on combinative technology to enhance the intestinal absorption of Olmesartan medoxomil (OLM), a potent antihypertensive agent with limited oral bioavailability. Two combinative approaches were employed and then characterized. In vitro intestinal absorption of OLM nanosuspension and plain OLM was studied using non-everted rat intestinal sac model. Optimal OLM nanosuspension was prepared by a combination of ball milling and probe sonication using stabilizer, Poloxamer 407. The formula exhibited particle size of 469.9 nm and zeta potential of -19.1 mV, which was subjected to ex vivo studies. The flux and apparent permeability coefficient in intestine from OLM nanosuspension was higher than the plain drug, thereby suggesting better drug delivery.
| Original language | English |
|---|---|
| Pages (from-to) | 57-63 |
| Number of pages | 7 |
| Journal | Saudi Pharmaceutical Journal |
| Volume | 24 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmaceutical Science
Cite this
}
Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension : Preparation by combinative technology. / Attari, Zenab; Bhandari, Amita; Jagadish, P. C.; Lewis, Shaila.
In: Saudi Pharmaceutical Journal, Vol. 24, No. 1, 2016, p. 57-63.Research output: Contribution to journal › Article
TY - JOUR
T1 - Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension
T2 - Preparation by combinative technology
AU - Attari, Zenab
AU - Bhandari, Amita
AU - Jagadish, P. C.
AU - Lewis, Shaila
PY - 2016
Y1 - 2016
N2 - The purpose of this study was to develop nanosuspension based on combinative technology to enhance the intestinal absorption of Olmesartan medoxomil (OLM), a potent antihypertensive agent with limited oral bioavailability. Two combinative approaches were employed and then characterized. In vitro intestinal absorption of OLM nanosuspension and plain OLM was studied using non-everted rat intestinal sac model. Optimal OLM nanosuspension was prepared by a combination of ball milling and probe sonication using stabilizer, Poloxamer 407. The formula exhibited particle size of 469.9 nm and zeta potential of -19.1 mV, which was subjected to ex vivo studies. The flux and apparent permeability coefficient in intestine from OLM nanosuspension was higher than the plain drug, thereby suggesting better drug delivery.
AB - The purpose of this study was to develop nanosuspension based on combinative technology to enhance the intestinal absorption of Olmesartan medoxomil (OLM), a potent antihypertensive agent with limited oral bioavailability. Two combinative approaches were employed and then characterized. In vitro intestinal absorption of OLM nanosuspension and plain OLM was studied using non-everted rat intestinal sac model. Optimal OLM nanosuspension was prepared by a combination of ball milling and probe sonication using stabilizer, Poloxamer 407. The formula exhibited particle size of 469.9 nm and zeta potential of -19.1 mV, which was subjected to ex vivo studies. The flux and apparent permeability coefficient in intestine from OLM nanosuspension was higher than the plain drug, thereby suggesting better drug delivery.
UR - http://www.scopus.com/inward/record.url?scp=84926144210&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926144210&partnerID=8YFLogxK
U2 - 10.1016/j.jsps.2015.03.008
DO - 10.1016/j.jsps.2015.03.008
M3 - Article
VL - 24
SP - 57
EP - 63
JO - Saudi Pharmaceutical Journal
JF - Saudi Pharmaceutical Journal
SN - 1319-0164
IS - 1
ER -